CryptoCondom
Crypto Market Commentary
Absci insiders are buying ahead of the ABS-201 interim readouts that now define the company's value. Outside directors Frans Van Houten, former Philips CEO, and Menelas Pangalos, former AstraZeneca biopharma R&D head, raised their stakes 172% and 527% in open-market trades, with no compensation incentive to support the stock. Chief Innovation Officer Andreas Busch bought $229K on March 12, 2026, nine days into his announced retirement, when retiring executives usually sell. x.comÂ
Absci has a unique moat as the only biotech, public or private, targeting non-drug-affiliated antibody targets, and its M&A chances are high as interest in AI-augmented therapeutics grows. AI will spread through every part of oncology and medical therapeutics, starting with tailored genome testing and proteomics. Absci is funded through 2028 and backed by AMD and Oracle for guaranteed compute. x.comÂ
Sivers Semiconductors' CEO buying stock is a bullish signal. @napoleon21st notes the CEO just bought over a quarter million dollars' worth. Insider buys tend to be bullish, while insider sells are not necessarily bearish because insiders sell for many personal reasons; neither is a clear signal, much as options flow reveals positioning without revealing intent. x.com x.comÂ
Insider buying signals that Uber is a buy: the CEO bought $10M of shares and the COO $5.3M, and Nancy Pelosi bought calls. Insiders buy for one reason, making this a good time to add. x.comÂ
Absci's pipeline looks no further along than it was years ago, yet the stock has risen with the biotech sector. x.comÂ
Absci is a binary-risk biotech, either a multibagger or a total failure, and less tempting than AbCellera's AI antibody platform. Its losses are large and persistent, and as cash dwindles more dilution should follow, with the share count still rising. Unlike AbCellera, it lacks solid partner programs and a robust build-out. The stock is stuck between $2.50 and $6.50: bad trial data could send it back to the bottom, while positive data or a new partnership could break it out. x.comÂ
